Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer.
- 1 April 1997
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (4) , 1354-1366
- https://doi.org/10.1200/jco.1997.15.4.1354
Abstract
PURPOSEWe investigated quality and efficacy criteria of an autologous, physically and immunologically purified, Newcastle disease virus (NDV)-modified, irradiated tumor-cell vaccine (ATV-NDV) by an...Keywords
This publication has 0 references indexed in Scilit: